Quest Diagnostics Reports Strong Q1 Results and Raises Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2024
0mins
Should l Buy DGX?
Source: Fool
Quest Diagnostics Inc. shares rose 5.45% as the stock reached a 20-day high, following the company's impressive Q1 earnings report.
The company reported a 9.2% year-over-year revenue growth, reaching net revenues of $2.895 billion, and an adjusted diluted EPS increase of 15.5% to $2.50. Additionally, Quest raised its full-year revenue guidance to between $11.78 billion and $11.90 billion, reflecting management's optimistic outlook for future performance. This strong performance has bolstered investor confidence in the company's financial health.
The positive results and guidance upgrade indicate that Quest Diagnostics is well-positioned for continued growth in the medical testing sector, attracting investor interest and enhancing its market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 189.130
Low
190.00
Averages
203.33
High
210.00
Current: 189.130
Low
190.00
Averages
203.33
High
210.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
2026 Market Cap Madness Championship Recap
- Championship Showdown: The 2026 Market Cap Madness Championship featured Emily Flippen facing off against undefeated challenger Loren Horst, showcasing intense competition that captivated many investors.
- Game Mechanics: Contestants were required to provide market cap ranges for randomly mentioned stocks, scoring points by agreeing or disagreeing, highlighting the significance of market caps in investment decisions.
- Stock Performance Analysis: During the game, Texas Instruments' market cap was assessed at $177.50 billion, underscoring its strong position in the semiconductor industry and reflecting investor confidence in its future growth.
- Final Outcome: Emily emerged victorious with an 8-2 score, solidifying her status as the Market Cap Game Show World Champion, emphasizing her keen insights into market dynamics and effective investment strategies.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Size: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5% interest rate, expected to close on May 6, 2026, providing the company with substantial funding to support its operations and growth.
- Debt Management: The net proceeds from this offering will be used for general corporate purposes, including potential repayment of maturing 3.45% notes, indicating the company's strategic intent to optimize its capital structure and reduce financial costs.
- Market Reaction: Following the announcement, Quest Diagnostics' stock price dipped 0.49% in after-hours trading to $195.65, reflecting market caution regarding the new debt issuance.
- Performance Outlook: Quest Diagnostics raised its 2026 revenue guidance to between $11.78 billion and $11.9 billion, with adjusted EPS expectations of $10.63 to $10.83, demonstrating the company's confidence in future performance and growth potential.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Overview: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5.000% interest rate, expected to close on May 6, 2026, indicating the company's active engagement in capital markets and financing capabilities.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized for general corporate purposes, including the repayment of $500 million in 3.45% senior notes maturing on June 1, 2026, aimed at optimizing the company's capital structure and reducing financial costs.
- Positive Market Response: The issuance of these notes has garnered attention in the market, reflecting investor confidence in Quest Diagnostics, which may enhance the company's competitive position in the medical diagnostics sector.
- Cautious Future Outlook: Despite demonstrating strong financing capabilities, the company must remain vigilant regarding economic volatility and regulatory changes that could impact future performance, ensuring ongoing financial health and market standing.
See More
Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
2026 Market Cap Madness Championship Recap
- Championship Showdown: The 2026 Market Cap Madness Championship featured Emily Flippen facing off against undefeated challenger Loren Horst, showcasing intense competition that captivated many investors.
- Game Mechanics: Contestants were required to provide market cap ranges for randomly mentioned stocks, scoring points by agreeing or disagreeing, highlighting the significance of market caps in investment decisions.
- Stock Performance Analysis: During the game, Texas Instruments' market cap was assessed at $177.50 billion, underscoring its strong position in the semiconductor industry and reflecting investor confidence in its future growth.
- Final Outcome: Emily emerged victorious with an 8-2 score, solidifying her status as the Market Cap Game Show World Champion, emphasizing her keen insights into market dynamics and effective investment strategies.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Size: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5% interest rate, expected to close on May 6, 2026, providing the company with substantial funding to support its operations and growth.
- Debt Management: The net proceeds from this offering will be used for general corporate purposes, including potential repayment of maturing 3.45% notes, indicating the company's strategic intent to optimize its capital structure and reduce financial costs.
- Market Reaction: Following the announcement, Quest Diagnostics' stock price dipped 0.49% in after-hours trading to $195.65, reflecting market caution regarding the new debt issuance.
- Performance Outlook: Quest Diagnostics raised its 2026 revenue guidance to between $11.78 billion and $11.9 billion, with adjusted EPS expectations of $10.63 to $10.83, demonstrating the company's confidence in future performance and growth potential.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Overview: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5.000% interest rate, expected to close on May 6, 2026, indicating the company's active engagement in capital markets and financing capabilities.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized for general corporate purposes, including the repayment of $500 million in 3.45% senior notes maturing on June 1, 2026, aimed at optimizing the company's capital structure and reducing financial costs.
- Positive Market Response: The issuance of these notes has garnered attention in the market, reflecting investor confidence in Quest Diagnostics, which may enhance the company's competitive position in the medical diagnostics sector.
- Cautious Future Outlook: Despite demonstrating strong financing capabilities, the company must remain vigilant regarding economic volatility and regulatory changes that could impact future performance, ensuring ongoing financial health and market standing.
See More
Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
